We would like to inform you about the new 2019 External Quality Control Program of Monitoring of Biotherapies, organized by the CTCB (a French independent association accredited to develop and run External Quality Assessment program).
This 2019 program, which will be in English, concerns the dosages of Infliximab, anti-Infliximab antibodies and Adalimumab, anti-Adalimumab antibodies.
The Registration Form of the CTCB contains all the detailed information on this program. As you will see, a pilot study on Vedolizumab is also planned to take place later on.
We kindly ask you to register directly with the CTCB by completing the Registration Form.
Please note that the deadline for the CTCB to receive the applications is 21st December 2018.
Please do not hesitate to get back to us should you need additional information.
